Clinical trial
A Phase 2, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of the Anti-GM-CSF Monoclonal Antibody KB003 in Subjects With Active Rheumatoid Arthritis and Inadequate Prior Treatment Outcome From Biologic Therapy
NCT00995449 is registered in ClinicalTrials.gov with Humanigen, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of the Anti-GM-CSF Monoclonal Antibody KB003 in Subjects With Active Rheumatoid Arthritis and Inadequate Prior Treatment Outcome From Biologic Therapy
- Lead sponsor
- Humanigen, Inc.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- January 31, 2010
- Completion date
- February 29, 2012
- Enrollment
- 9 (actual)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.
rheumatoid arthritis